Peptides

Human PD-L1 inhibitor V - 1 mg

$141.00
Check your price
  • Cat.Number : AS-65585
  • Availability :
    In stock

Alternative choices

Quantity

Programed cell death 1 (PD-1) receptor and its ligand PD-L1 are crucial immune checkpoints to downregulate T cell activation, tolerance and immunopathology. Several types of cancer cells were identified to overexpress PD-L1 so as to escape from the PD-1/PD-L1 immunosurveillance mechanism. This peptide, hPDL-1 inhibitor V binds to human PD-1 and inhibits PD-1/PD-L1 binding. It has anchor residues (underlined), LDYVNRRKMYQ that show a great impact on the binding of hPD-L1 to hPD-1. Developing inhibitors specifically blocking the PD-1/PD-L1 pathway became popular approach to cancer treatment.

Specifications

Chemistry
Sequence one letter code
  • LDYVNRRKMYQ
Sequence three letter code
  • H-Leu-Asp-Tyr-Val-Asn-Arg-Arg-Lys-Met-Tyr-Gln-OH
Molecular Formula
  • C65H104N20O18S1
Molecular Mass/ Weight
  • 1485.8
Modification
Conjugation
  • Unconjugated
Quantity & Purity
Purity
  • Peak Area by HPLC ≥95%
Storage & stability
Form
  • Lyophilized
Storage Conditions
  • - 20 °C
Activity
Biomarker Target
Research Area
Sub-category Research Area
Usage
  • Research use
Source
Source / Species
  • human

You may also be interested in the following product(s)

IMG-EN-AS-60877-01.jpg

Thrombospondin (TSP-1) Inhibitor, LSKL - 1 mg

Cat.Number : AS-60877
$88.00 Excl. Tax

References

A current perspective on cancer immune therapy: step-by-step approach to constructing the magic bullet.

Clin Transl Med . 2017 Dec 01 ; 6(1) 3 | DOI : 10.1186/s40169-016-0130-5

  • G. D'Errico
  • et al

Discovery of peptide inhibitors targeting human programmed death 1 (PD-1) receptor

Oncotarget . 2016 Oct 04 ; 7(40) 64967 | DOI : 10.18632/oncotarget.11274

  • Q. Li
  • et al

The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation

Front Immunol . 2016 Dec 12 ; 7 550 | DOI : 10.3389/fimmu.2016.00550

  • K. Bardhan
  • et al